openPR Logo
Press release

AXS-05 for Treatment-Resistant Depression: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players - Axsome Therapeutics

02-09-2024 04:48 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

DelveInsight has released a comprehensive report titled "AXS-05 Market Forecast" offering a thorough examination and predictive insights into the AXS-05 market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The extensive report offers a thorough examination of the market potential and market share of AXS-05 in the therapeutics landscape for Treatment-Resistant Depression across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of AXS-05, encompassing both clinical and commercial dimensions. Key parameters such as the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

AXS-05 Drug Insights
AXS-05 represents a groundbreaking advancement in the realm of pharmacology, offering a unique oral formulation with investigational properties as an NMDA receptor antagonist. This innovative compound harnesses the combined therapeutic potential of dextromethorphan (DM) and bupropion in a proprietary blend, demonstrating multimodal activity. Its development is specifically geared towards addressing a spectrum of central nervous system (CNS) conditions, showcasing promise as a potential treatment option in this complex therapeutic landscape.

The ongoing development of AXS-05 marks a significant milestone in the field of neuropsychiatry, with its potential applications extending to the treatment of major depressive disorder (MDD), Alzheimer's disease agitation, and smoking cessation. Notably, the compound has garnered notable recognition from the FDA, securing Breakthrough Therapy designation for its efficacy in managing both MDD and Alzheimer's disease agitation. This acknowledgment underscores the compound's promising therapeutic profile and the pressing need for innovative solutions in addressing these challenging neurological conditions.

Get a detailed overview of the AXS-05 drug and stay ahead of the competition by leveraging key insights:
https://www.delveinsight.com/sample-request/axs-05-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Key Highlights of the AXS-05 Market Report
• The report includes a projected assessment of AXS-05 sales for Treatment-Resistant Depression up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Treatment-Resistant Depression.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on AXS-05 for Treatment-Resistant Depression.

Why AXS-05 Market Report?
• The projected market data for AXS-05 in the context of Treatment-Resistant Depression will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of AXS-05, aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for AXS-05 will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug's positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the AXS-05 market in the field of Treatment-Resistant Depression across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Treatment-Resistant Depression. This multifaceted approach ensures a comprehensive understanding of the AXS-05 market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for AXS-05 will facilitate a detailed analysis of the drug's clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of AXS-05.

Explore key clinical, commercial, and regulatory milestones associated with AXS-05 by visiting:
https://www.delveinsight.com/sample-request/axs-05-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Contents of the Report
1. Report Introduction
2. AXS-05 Overview in Treatment-Resistant Depression
3. Competitive Landscape (Key Assessment of the Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies Analysis)
5. AXS-05 Market Assessment
6. SWOT Analysis
7. Analysts' Views
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the AXS-05 Market Report @
https://www.delveinsight.com/sample-request/axs-05-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
----------------------------------------------------------------------------------------------------------------------------------

Other Related Reports By DelveInsight
Treatment-Resistant Depression Pipeline Insight
DelveInsight's "Treatment-Resistant Depression Pipeline Insight" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Treatment-Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Treatment-Resistant Depression Therapeutics market include Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, and ATAI Life Sciences, and others.
Visit & explore how the Treatment-Resistant Depression therapeutics pipeline is evolving, at:
https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release AXS-05 for Treatment-Resistant Depression: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players - Axsome Therapeutics here

News-ID: 3379811 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Depression

Ace Therapeutics Accelerates Preclinical Depression Investigation by Providing D …
Ace Therapeutics released depression-related behavior tests to accelerate preclinical depression research. New York, USA - December 24, 2024 - Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests [https://www.acetherapeutics.com/psychiatry/depression-behavior-tests.html] in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and expedite
Postpartum Depression Global Market Report 2024 - Postpartum Depression Market S …
The Business Research Company recently released a comprehensive report on the Global Postpartum Depression Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The postpartum depression market
Depression Apps Market - Tools for Resilience, Tools for Life: Depression Apps f …
Newark, New Castle, USA: The "Depression Apps Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Depression Apps Market: https://www.growthplusreports.com/report/depression-apps-market/8782 This latest report researches the industry structure, sales, revenue,
Depression Apps Market - Navigating the Path to Mental Wellbeing: Harnessing the …
Newark, New Castle, USA - new report, titled Depression Apps Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Depression Apps market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Depression Apps market. The report offers an overview of the market, which
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive